

MARC Measure Review Schedule

2025-2027

These dates are approximate and may be subject to change based on organizational needs.

2025	
March	Chlamydia Screening in Women*
June	Childhood Immunization Status (Combo 10)* Immunizations for Adolescents (Combo 2)*
September	Controlling High Blood Pressure*
2026	
March	Breast Cancer Screening* Cervical Cancer Screening* Colorectal Cancer Screening^
June	Depression Suite (Adults & Adolescents)
September	Optimal Diabetes Care Optimal Vascular Care Eye Exam for Patients with Diabetes*
2027	
March	Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis* Follow-up Care for Children Prescribed ADHD Medication: Initiation Phase*
June	Adolescent Mental Health and/or Depression Screening Optimal Asthma Control (Adults & Children)
September	Osteoporosis Management in Women with Acute Fracture*

*HEDIS measure; NCQA is measure steward.

^NCQA is measure steward, but MNCM receives data directly from medical groups/clinics.

NOTES:

- **Follow-up Care for Children Prescribed ADHD Medication:** In 2024, MARC recommended that MNCM change from reporting “Continuation & Maintenance Phase” rate to reporting “Initiation Phase” rate. For the 2024 measurement year, statewide and medical group results will be privately reported to medical groups/health plans. Public reporting of this phase is anticipated for 2025 measurement year.
- **Optimal Asthma Control:** Beginning in December 2024, a measure redesign workgroup began work to update the measure specifications based on MARC’s review of the measure in June 2024.
- **Orthopedic and Cancer measures:** The preliminary statewide results for the Discectomy/Laminectomy, Lumbar Fusion, Total Knee Replacement, and Oncology Suite measures will be brought to MARC in December 2025. MARC will review the preliminary results and provide recommendations on whether these measures should be publicly reported in 2026.

UPDATED: March 2025